<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34464655</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1089-8638</ISSN><JournalIssue CitedMedium="Internet"><Volume>434</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of molecular biology</Title><ISOAbbreviation>J Mol Biol</ISOAbbreviation></Journal><ArticleTitle>Nuclear-Import Receptors Counter Deleterious Phase Transitions in Neurodegenerative Disease.</ArticleTitle><Pagination><StartPage>167220</StartPage><MedlinePgn>167220</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jmb.2021.167220</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-2836(21)00453-8</ELocationID><Abstract><AbstractText>Nuclear-import receptors (NIRs) engage nuclear-localization signals (NLSs) of polypeptides in the cytoplasm and transport these cargo across the size-selective barrier of the nuclear-pore complex into the nucleoplasm. Beyond this canonical role in nuclear transport, NIRs operate in the cytoplasm to chaperone and disaggregate NLS-bearing clients. Indeed, NIRs can inhibit and reverse functional and deleterious phase transitions of their cargo, including several prominent neurodegenerative disease-linked RNA-binding proteins (RBPs) with prion-like domains (PrLDs), such as TDP-43, FUS, EWSR1, TAF15, hnRNPA1, and hnRNPA2. Importantly, elevated NIR expression can mitigate degenerative phenotypes connected to aberrant cytoplasmic aggregation of RBPs with PrLDs. Here, we review recent discoveries that NIRs can also antagonize aberrant interactions and toxicity of arginine-rich, dipeptide-repeat proteins that are associated with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) caused by G<sub>4</sub>C<sub>2</sub> hexanucleotide repeat expansions in the first intron of C9ORF72. We also highlight recent findings that multiple NIR family members can prevent and reverse liquid-liquid phase separation of specific clients bearing RGG motifs in an NLS-independent manner. Finally, we discuss strategies to enhance NIR activity or expression, which could have therapeutic utility for several neurodegenerative disorders, including ALS, FTD, multisystem proteinopathy, limbic-predominant age-related TDP-43 encephalopathy, tauopathies, and related diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Odeh</LastName><ForeName>Hana M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fare</LastName><ForeName>Charlotte M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Biochemistry and Molecular Biophysics Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: https://twitter.com/CharlotteFare.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shorter</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Biochemistry and Molecular Biophysics Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: jshorter@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 NS090205</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS111870</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM099836</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG061784</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG065854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008275</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Mol Biol</MedlineTA><NlmUniqueID>2985088R</NlmUniqueID><ISSNLinking>0022-2836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018160">Receptors, Cytoplasmic and Nuclear</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D021581" MajorTopicYN="N">Active Transport, Cell Nucleus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044367" MajorTopicYN="N">Phase Transition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018160" MajorTopicYN="N">Receptors, Cytoplasmic and Nuclear</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS/FTD</Keyword><Keyword MajorTopicYN="N">FUS</Keyword><Keyword MajorTopicYN="N">chaperone</Keyword><Keyword MajorTopicYN="N">nuclear-import receptor</Keyword><Keyword MajorTopicYN="N">phase separation</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest H.M.O. and C.M.F. declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. J.S. is a consultant for Dewpoint Therapeutics, Maze Therapeutics, Vivid Sciences, Korro Bio, ADRx, and RBNC Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>31</Day><Hour>20</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34464655</ArticleId><ArticleId IdType="mid">NIHMS1736740</ArticleId><ArticleId IdType="pmc">PMC8748273</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2021.167220</ArticleId><ArticleId IdType="pii">S0022-2836(21)00453-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Portz B, Lee BL, Shorter J. FUS and TDP-43 Phases in Health and Disease. Trends Biochem Sci. 2021;46:550&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8195841</ArticleId><ArticleId IdType="pubmed">33446423</ArticleId></ArticleIdList></Reference><Reference><Citation>Cushman M, Johnson BS, King OD, Gitler AD, Shorter J. Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci. 2010;123:1191&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848109</ArticleId><ArticleId IdType="pubmed">20356930</ArticleId></ArticleIdList></Reference><Reference><Citation>King OD, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 2012;1462:61&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372647</ArticleId><ArticleId IdType="pubmed">22445064</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YR, King OD, Shorter J, Gitler AD. Stress granules as crucibles of ALS pathogenesis. J Cell Biol. 2013;201:361&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639398</ArticleId><ArticleId IdType="pubmed">23629963</ArticleId></ArticleIdList></Reference><Reference><Citation>March ZM, King OD, Shorter J. Prion-like domains as epigenetic regulators, scaffolds for subcellular organization, and drivers of neurodegenerative disease. Brain Res. 2016;1647:9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003744</ArticleId><ArticleId IdType="pubmed">26996412</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Shorter J. Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies. Cold Spring Harb Perspect Med. 2017;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5580514</ArticleId><ArticleId IdType="pubmed">27920024</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison AF, Shorter J. RNA-binding proteins with prion-like domains in health and disease. Biochem J. 2017;474:1417&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5639257</ArticleId><ArticleId IdType="pubmed">28389532</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VM, Trojanowski JQ. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci. 2011;13:38&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285250</ArticleId><ArticleId IdType="pubmed">22127299</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G, Gautier O, Tassoni-Tsuchida E, Ma XR, Gitler AD. ALS Genetics: Gains, Losses, and Implications for Future Therapies. Neuron. 2020;108:822&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackrel ME, Shorter J. Engineering enhanced protein disaggregases for neurodegenerative disease. Prion. 2015;9:90&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4601286</ArticleId><ArticleId IdType="pubmed">25738979</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackrel ME, Shorter J. Protein-Remodeling Factors As Potential Therapeutics for Neurodegenerative Disease. Front Neurosci. 2017;11:99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5328956</ArticleId><ArticleId IdType="pubmed">28293166</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J. Hsp104: a weapon to combat diverse neurodegenerative disorders. Neurosignals. 2008;16:63&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">18097161</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J. Designer protein disaggregases to counter neurodegenerative disease. Curr Opin Genet Dev. 2017;44:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5447488</ArticleId><ArticleId IdType="pubmed">28208059</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J. Engineering therapeutic protein disaggregases. Mol Biol Cell. 2016;27:1556&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4865313</ArticleId><ArticleId IdType="pubmed">27255695</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Fare CM, Shorter J. Therapeutic Dissolution of Aberrant Phases by Nuclear-Import Receptors. Trends Cell Biol. 2019;29:308&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6750949</ArticleId><ArticleId IdType="pubmed">30660504</ArticleId></ArticleIdList></Reference><Reference><Citation>Darling AL, Shorter J. Combating deleterious phase transitions in neurodegenerative disease. Biochim Biophys Acta Mol Cell Res. 2021;1868:118984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7965345</ArticleId><ArticleId IdType="pubmed">33549703</ArticleId></ArticleIdList></Reference><Reference><Citation>Fare CM, Shorter J. (Dis)Solving the problem of aberrant protein states. Dis Model Mech. 2021;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8126477</ArticleId><ArticleId IdType="pubmed">33942880</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Kim HJ, Wang H, Monaghan J, Freyermuth F, Sung JC, et al. Nuclear-Import Receptors Reverse Aberrant Phase Transitions of RNA-Binding Proteins with Prion-like Domains. Cell. 2018;173:677&#x2013;92 e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911940</ArticleId><ArticleId IdType="pubmed">29677512</ArticleId></ArticleIdList></Reference><Reference><Citation>Springhower CE, Rosen MK, Chook YM. Karyopherins and condensates. Curr Opin Cell Biol. 2020;64:112&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371519</ArticleId><ArticleId IdType="pubmed">32474299</ArticleId></ArticleIdList></Reference><Reference><Citation>Chook YM, Suel KE. Nuclear import by karyopherin-betas: recognition and inhibition. Biochim Biophys Acta. 2011;1813:1593&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135726</ArticleId><ArticleId IdType="pubmed">21029754</ArticleId></ArticleIdList></Reference><Reference><Citation>Soniat M, Chook YM. Nuclear localization signals for four distinct karyopherin-beta nuclear import systems. Biochem J. 2015;468:353&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">26173234</ArticleId></ArticleIdList></Reference><Reference><Citation>Allegretti M, Zimmerli CE, Rantos V, Wilfling F, Ronchi P, Fung HKH, et al. In-cell architecture of the nuclear pore and snapshots of its turnover. Nature. 2020;586:796&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">32879490</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohr D, Frey S, Fischer T, Guttler T, Gorlich D. Characterisation of the passive permeability barrier of nuclear pore complexes. EMBO J. 2009;28:2541&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2728435</ArticleId><ArticleId IdType="pubmed">19680228</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey S, Gorlich D. A saturated FG-repeat hydrogel can reproduce the permeability properties of nuclear pore complexes. Cell. 2007;130:512&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17693259</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey S, Richter RP, Gorlich D. FG-rich repeats of nuclear pore proteins form a three-dimensional meshwork with hydrogel-like properties. Science. 2006;314:815&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082456</ArticleId></ArticleIdList></Reference><Reference><Citation>Labokha AA, Gradmann S, Frey S, Hulsmann BB, Urlaub H, Baldus M, et al. Systematic analysis of barrier-forming FG hydrogels from Xenopus nuclear pore complexes. EMBO J. 2013;32:204&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3553378</ArticleId><ArticleId IdType="pubmed">23202855</ArticleId></ArticleIdList></Reference><Reference><Citation>Celetti G, Paci G, Caria J, VanDelinder V, Bachand G, Lemke EA. The liquid state of FG-nucleoporins mimics permeability barrier properties of nuclear pore complexes. J Cell Biol. 2020;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7039189</ArticleId><ArticleId IdType="pubmed">31723007</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey S, Rees R, Schunemann J, Ng SC, Funfgeld K, Huyton T, et al. Surface Properties Determining Passage Rates of Proteins through Nuclear Pores. Cell. 2018;174:202&#x2013;17 e9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29958108</ArticleId></ArticleIdList></Reference><Reference><Citation>Maharana S, Wang J, Papadopoulos DK, Richter D, Pozniakovsky A, Poser I, et al. RNA buffers the phase separation behavior of prion-like RNA binding proteins. Science. 2018;360:918&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091854</ArticleId><ArticleId IdType="pubmed">29650702</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, Gleixner AM, Mauna JC, Gomes E, DeChellis-Marks MR, Needham PG, et al. RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43. Neuron. 2019;102:321&#x2013;38 e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Lu S, Gasior K, Singh D, Vazquez-Sanchez S, Tapia O, et al. HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells. Science. 2021;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8286096</ArticleId><ArticleId IdType="pubmed">33335017</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshizawa T, Ali R, Jiou J, Fung HYJ, Burke KA, Kim SJ, et al. Nuclear Import Receptor Inhibits Phase Separation of FUS through Binding to Multiple Sites. Cell. 2018;173:693&#x2013;705 e22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234985</ArticleId><ArticleId IdType="pubmed">29677513</ArticleId></ArticleIdList></Reference><Reference><Citation>Qamar S, Wang G, Randle SJ, Ruggeri FS, Varela JA, Lin JQ, et al. FUS Phase Separation Is Modulated by a Molecular Chaperone and Methylation of Arginine Cation-pi Interactions. Cell. 2018;173:720&#x2013;34 e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5927716</ArticleId><ArticleId IdType="pubmed">29677515</ArticleId></ArticleIdList></Reference><Reference><Citation>Baade I, Hutten S, Sternburg EL, Porschke M, Hofweber M, Dormann D, et al. The RNA-binding protein FUS is chaperoned and imported into the nucleus by a network of import receptors. J Biol Chem. 2021;296:100659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8131929</ArticleId><ArticleId IdType="pubmed">33857479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofweber M, Hutten S, Bourgeois B, Spreitzer E, Niedner-Boblenz A, Schifferer M, et al. Phase Separation of FUS Is Suppressed by Its Nuclear Import Receptor and Arginine Methylation. Cell. 2018;173:706&#x2013;19 e13.</Citation><ArticleIdList><ArticleId IdType="pubmed">29677514</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutten S, Usluer S, Bourgeois B, Simonetti F, Odeh HM, Fare CM, et al. Nuclear Import Receptors Directly Bind to Arginine-Rich Dipeptide Repeat Proteins and Suppress Their Pathological Interactions. Cell Rep. 2020;33:108538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7814465</ArticleId><ArticleId IdType="pubmed">33357437</ArticleId></ArticleIdList></Reference><Reference><Citation>Niaki AG, Sarkar J, Cai X, Rhine K, Vidaurre V, Guy B, et al. Loss of Dynamic RNA Interaction and Aberrant Phase Separation Induced by Two Distinct Types of ALS/FTD-Linked FUS Mutations. Mol Cell. 2020;77:82&#x2013;94 e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6943187</ArticleId><ArticleId IdType="pubmed">31630970</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhine K, Makurath MA, Liu J, Skanchy S, Lopez C, Catalan KF, et al. ALS/FTLD-Linked Mutations in FUS Glycine Residues Cause Accelerated Gelation and Reduced Interactions with Wild-Type FUS. Mol Cell. 2020;80:666&#x2013;81 e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7688085</ArticleId><ArticleId IdType="pubmed">33159856</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez A, Mannen T, Cagatay T, Fujiwara A, Matsumura H, Niesman AB, et al. Mechanism of karyopherin-beta2 binding and nuclear import of ALS variants FUS(P525L) and FUS(R495X). Sci Rep. 2021;11:3754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7881136</ArticleId><ArticleId IdType="pubmed">33580145</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakel S, Mingot JM, Schwarzmaier P, Hartmann E, Gorlich D. Importins fulfil a dual function as nuclear import receptors and cytoplasmic chaperones for exposed basic domains. EMBO J. 2002;21:377&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125346</ArticleId><ArticleId IdType="pubmed">11823430</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou CC, Zhang Y, Umoh ME, Vaughan SW, Lorenzini I, Liu F, et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat Neurosci. 2018;21:228&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyake Y, Keusch JJ, Decamps L, Ho-Xuan H, Iketani S, Gut H, et al. Influenza virus uses transportin 1 for vRNP debundling during cell entry. Nat Microbiol. 2019;4:578&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">30692667</ArticleId></ArticleIdList></Reference><Reference><Citation>King MR, Petry S. Phase separation of TPX2 enhances and spatially coordinates microtubule nucleation. Nat Commun. 2020;11:270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6959270</ArticleId><ArticleId IdType="pubmed">31937751</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackel S, Summerer AK, Thommes CM, Pan X, Voigt A, Schulz JB, et al. Nuclear import factor transportin and arginine methyltransferase 1 modify FUS neurotoxicity in Drosophila. Neurobiol Dis. 2015;74:76&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">25447237</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaru-Ampornpan P, Shen K, Lam VQ, Ali M, Doniach S, Jia TZ, et al. ATP-independent reversal of a membrane protein aggregate by a chloroplast SRP subunit. Nat Struct Mol Biol. 2010;17:696&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2917185</ArticleId><ArticleId IdType="pubmed">20424608</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Agrawal T, Zhu G, Yu S, Tao L, Lin J, et al. DAXX represents a new type of protein-folding enabler. Nature. 2021;doi:10.1038/s41586-021-03824-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03824-5</ArticleId><ArticleId IdType="pmc">PMC8485697</ArticleId><ArticleId IdType="pubmed">34408321</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu G, Harischandra DS, Ghaisas S, Zhang P, Prall W, Huang L, et al. TRIM11 Prevents and Reverses Protein Aggregation and Rescues a Mouse Model of Parkinson&#x2019;s Disease. Cell Rep. 2020;33:108418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7906527</ArticleId><ArticleId IdType="pubmed">33264628</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker JD, Shelton LB, Zheng D, Favretto F, Nordhues BA, Darling A, et al. Human cyclophilin 40 unravels neurotoxic amyloids. PLoS Biol. 2017;15:e2001336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5486962</ArticleId><ArticleId IdType="pubmed">28654636</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshizawa T, Guo L. Karyopherin-betas play a key role as a phase separation regulator. J Biochem. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8457648</ArticleId><ArticleId IdType="pubmed">34223614</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikhaleva S, Lemke EA. Beyond the Transport Function of Import Receptors: What&#x2019;s All the FUS about? Cell. 2018;173:549&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611746</ArticleId><ArticleId IdType="pubmed">29677508</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasha T, Zatorska A, Sharipov D, Rogelj B, Hortobagyi T, Hirth F. Karyopherin abnormalities in neurodegenerative proteinopathies. Brain. 2021;doi:10.1093/brain/awab201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab201</ArticleId><ArticleId IdType="pmc">PMC8194669</ArticleId><ArticleId IdType="pubmed">34019093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Gibbens B, Doty NS, Gomes-Pereira M, Huguet A, Stone MD, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci USA. 2011;108:260&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017129</ArticleId><ArticleId IdType="pubmed">21173221</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicic A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci. 2015;18:1226&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Vihola A, Palmio J, Danielsson O, Penttila S, Louiselle D, Pittman S, et al. Novel mutation in TNPO3 causes congenital limb-girdle myopathy with slow progression. Neurol Genet. 2019;5:e337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6515942</ArticleId><ArticleId IdType="pubmed">31192305</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura AL, Zupunski V, Troakes C, Kathe C, Fratta P, Howell M, et al. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain. 2010;133:1763&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472655</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Daigle JG, Cunningham KM, Coyne AN, Ruan K, Grima JC, et al. Stress Granule Assembly Disrupts Nucleocytoplasmic Transport. Cell. 2018;173:958&#x2013;71 e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon DA, Stepto A, Au WH, Adachi Y, Diaper DC, Hall R, et al. A feedback loop between dipeptide-repeat protein, TDP-43 and karyopherin-alpha mediates C9orf72-related neurodegeneration. Brain. 2018;141:2908&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6158706</ArticleId><ArticleId IdType="pubmed">30239641</ArticleId></ArticleIdList></Reference><Reference><Citation>Troakes C, Hortobagyi T, Vance C, Al-Sarraj S, Rogelj B, Shaw CE. Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS inclusions. Neuropathol Appl Neurobiol. 2013;39:553&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">22934812</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Valori CF, Ansorge O, Kretzschmar HA, Munoz DG, Kusaka H, et al. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations. Acta Neuropathol. 2012;124:705&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">22842875</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D, Madl T, Valori CF, Bentmann E, Tahirovic S, Abou-Ajram C, et al. Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS. EMBO J. 2012;31:4258&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3501225</ArticleId><ArticleId IdType="pubmed">22968170</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZC, Chook YM. Structural and energetic basis of ALS-causing mutations in the atypical proline-tyrosine nuclear localization signal of the Fused in Sarcoma protein (FUS). Proc Natl Acad Sci U S A. 2012;109:12017&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409756</ArticleId><ArticleId IdType="pubmed">22778397</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A, et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 2010;29:2841&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924641</ArticleId><ArticleId IdType="pubmed">20606625</ArticleId></ArticleIdList></Reference><Reference><Citation>Naruse H, Ishiura H, Mitsui J, Date H, Takahashi Y, Matsukawa T, et al. Molecular epidemiological study of familial amyotrophic lateral sclerosis in Japanese population by whole-exome sequencing and identification of novel HNRNPA1 mutation. Neurobiol Aging. 2018;61:255.e9&#x2013;.e16.</Citation><ArticleIdList><ArticleId IdType="pubmed">29033165</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Shu S, Wang RR, Liu F, Cui B, Guo XN, et al. Whole-exome sequencing identifies a missense mutation in hnRNPA1 in a family with flail arm ALS. Neurology. 2016;87:1763&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">27694260</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA, Lemay N, Ko HK, Zhou H, Burke C, Kwiatkowski TJ Jr., et al. Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum Mol Genet. 2010;19:4160&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2981014</ArticleId><ArticleId IdType="pubmed">20699327</ArticleId></ArticleIdList></Reference><Reference><Citation>Beijer D, Kim H, Guo L, O&#x2019;Donovan K, Mademan I, Deconinck T, et al. DEFINING THE DIVERSITY OF HNRNPA1 MUTATIONS IN CLINICAL PHENOTYPE AND PATHOMECHANISM. medRxiv. 2021:2021.02.02.21250330.</Citation></Reference><Reference><Citation>Kim HJ, Mohassel P, Donkervoort S, Guo L, O&#x2019;Donovan K, Coughlin M, et al. Specific heterozygous frameshift variants in hnRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy. medRxiv. 2021:2021.04.08.21254942.</Citation></Reference><Reference><Citation>Goodman LD, Cope H, Nil Z, Ravenscroft TA, Charng WL, Lu S, et al. TNPO2 variants associate with human developmental delays, neurologic deficits, and dysmorphic features and alter TNPO2 activity in Drosophila. Am J Hum Genet. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8456166</ArticleId><ArticleId IdType="pubmed">34314705</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Odeh HM, Shorter J. Arginine-rich dipeptide-repeat proteins as phase disruptors in C9-ALS/FTD. Emerg Top Life Sci. 2020;4:293&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7935415</ArticleId><ArticleId IdType="pubmed">32639008</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALSFTD. Neuron. 2011;72:257&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler AD, Tsuiji H. There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS. Brain research. 2016;1647:19&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003651</ArticleId><ArticleId IdType="pubmed">27059391</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacoangeli A, Al Khleifat A, Jones AR, Sproviero W, Shatunov A, Opie-Martin S, et al. C9orf72 intermediate expansions of 24&#x2013;30 repeats are associated with ALS. Acta Neuropathol Commun. 2019;7:115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6637621</ArticleId><ArticleId IdType="pubmed">31315673</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Arzberger T, Gr&#xe4;sser FA, Gijselinck I, May S, Rentzsch K, et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 2013;126:881&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Ba&#xf1;ez-Coronel M, Reid T, Pletnikova O, Lewis J, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci USA. 2013;110:E4968&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Gr&#xf6;nke S, Niccoli T, Ridler CE, Clayton EL, Devoy A, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science (New York, NY). 2014;345:1192&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, Tan W, Westergard T, Krishnamurthy K, Markandaiah SS, Shi Y, et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 2014;84:1213&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K-H, Zhang P, Kim HJ, Mitrea DM, Sarkar M, Freibaum BD, et al. C9orf72 Dipeptide Repeats Impair the Assembly, Dynamics, and Function of Membrane-Less Organelles. Cell. 2016;167:774&#x2013;88.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Guo L, Gonzales PK, Gendron TF, Wu Y, Jansen-West K, et al. Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity. Science. 2019;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524780</ArticleId><ArticleId IdType="pubmed">30765536</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook CN, Wu Y, Odeh HM, Gendron TF, Jansen-West K, Del Rosso G, et al. C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy. Sci Transl Med. 2020;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989020</ArticleId><ArticleId IdType="pubmed">32878979</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S, Bogaert E, Michiels E, Gijselinck I, Sieben A, Jovicic A, et al. Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. Sci Rep. 2016;6:20877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4751451</ArticleId><ArticleId IdType="pubmed">26869068</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee K-H, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525:129&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes LR, Duan L, Bowen K, Kalab P, Rothstein JD. C9orf72 arginine-rich dipeptide repeat proteins disrupt karyopherin-mediated nuclear import. eLife. 2020;9:e51685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7051184</ArticleId><ArticleId IdType="pubmed">32119645</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S, Holehouse AS, Weinhardt V, Kovacs D, Van Lindt J, Larabell C, et al. Spontaneous driving forces give rise to protein-RNA condensates with coexisting phases and complex material properties. Proc Natl Acad Sci U S A. 2019;116:7889&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6475405</ArticleId><ArticleId IdType="pubmed">30926670</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosravi B, Hartmann H, May S, M&#xf6;hl C, Ederle H, Michaelsen M, et al. Cytoplasmic poly-GA aggregates impair nuclear import of TDP-43 in C9orf72 ALS/FTLD. Hum Mol Genet. 2017;26:790&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5409121</ArticleId><ArticleId IdType="pubmed">28040728</ArticleId></ArticleIdList></Reference><Reference><Citation>McEachin ZT, Gendron TF, Raj N, Garc&#xed;a-Murias M, Banerjee A, Purcell RH, et al. Chimeric Peptide Species Contribute to Divergent Dipeptide Repeat Pathology in c9ALS/FTD and SCA36. Neuron. 2020;107:292&#x2013;305.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8138626</ArticleId><ArticleId IdType="pubmed">32375063</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Chung CG, Park SS, Lee D, Kim KM, Jeong Y, et al. Cytosolic calcium regulates cytoplasmic accumulation of TDP-43 through Calpain-A and Importin &#x3b1;3. eLife. 2020;9:e60132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7748415</ArticleId><ArticleId IdType="pubmed">33305734</ArticleId></ArticleIdList></Reference><Reference><Citation>Todd TW, McEachin ZT, Chew J, Burch AR, Jansen-West K, Tong J, et al. Hexanucleotide Repeat Expansions in c9FTD/ALS and SCA36 Confer Selective Patterns of Neurodegeneration In Vivo. Cell Rep. 2020;31:107616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7480900</ArticleId><ArticleId IdType="pubmed">32375043</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly AJ, Dacks JB, Field MC. Evolution of the Karyopherin-&#x3b2; Family of Nucleocytoplasmic Transport Factors; Ancient Origins and Continued Specialization. PLOS ONE. 2011;6:e19308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083441</ArticleId><ArticleId IdType="pubmed">21556326</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold M, Nath A, Hauber J, Kehlenbach RH. Multiple importins function as nuclear transport receptors for the Rev protein of human immunodeficiency virus type 1. J Biol Chem. 2006;281:20883&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">16704975</ArticleId></ArticleIdList></Reference><Reference><Citation>Baake M, Bauerle M, Doenecke D, Albig W. Core histones and linker histones are imported into the nucleus by different pathways. Eur J Cell Biol. 2001;80:669&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">11824786</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivic N, Potocnjak M, Solis-Mezarino V, Herzog F, Bilokapic S, Halic M. Fuzzy Interactions Form and Shape the Histone Transport Complex. Mol Cell. 2019;73:1191&#x2013;203 e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6436938</ArticleId><ArticleId IdType="pubmed">30824373</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakel S, Albig W, Kutay U, Bischoff FR, Schwamborn K, Doenecke D, et al. The importin beta/importin 7 heterodimer is a functional nuclear import receptor for histone H1. EMBO J. 1999;18:2411&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1171324</ArticleId><ArticleId IdType="pubmed">10228156</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhlhausser P, Muller EC, Otto A, Kutay U. Multiple pathways contribute to nuclear import of core histones. EMBO Rep. 2001;2:690&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1084005</ArticleId><ArticleId IdType="pubmed">11493596</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldmann I, Walde S, Kehlenbach RH. Nuclear import of c-Jun is mediated by multiple transport receptors. J Biol Chem. 2007;282:27685&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">17652081</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman ND, Yamamoto KR. Importin 7 and importin alpha/importin beta are nuclear import receptors for the glucocorticoid receptor. Mol Biol Cell. 2004;15:2276&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC404022</ArticleId><ArticleId IdType="pubmed">15004228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgeois B, Hutten S, Gottschalk B, Hofweber M, Richter G, Sternat J, et al. Nonclassical nuclear localization signals mediate nuclear import of CIRBP. Proc Natl Acad Sci U S A. 2020;117:8503&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165476</ArticleId><ArticleId IdType="pubmed">32234784</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A, Lee HO, Jawerth L, Maharana S, Jahnel M, Hein MY, et al. A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell. 2015;162:1066&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelini C, Marozzo R, Pinzan E, Pegoraro V, Molnar MJ, Torella A, et al. A new family with transportinopathy: increased clinical heterogeneity. Ther Adv Neurol Disord. 2019;12:1756286419850433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6558532</ArticleId><ArticleId IdType="pubmed">31217819</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe1;l E, Zima J, Hadzsiev K, Ito YA, Hartley T, Boycott KM, et al. A novel pathogenic variant in TNPO3 in a Hungarian family with limb-girdle muscular dystrophy 1F. Eur J Med Genet. 2019;62:103662.</Citation><ArticleIdList><ArticleId IdType="pubmed">31071488</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Mora S, De Wit F, Garc&#xed;a-Perez J, Bermejo M, L&#xf3;pez-Huertas MR, Mateos E, et al. The mutation of Transportin 3 gene that causes limb girdle muscular dystrophy 1F induces protection against HIV-1 infection. PLoS Pathog. 2019;15:e1007958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6715175</ArticleId><ArticleId IdType="pubmed">31465518</ArticleId></ArticleIdList></Reference><Reference><Citation>Meli&#xe0; MJ, Kubota A, Ortolano S, V&#xed;lchez JJ, G&#xe1;mez J, Tanji K, et al. Limb-girdle muscular dystrophy 1F is caused by a microdeletion in the transportin 3 gene. Brain. 2013;136:1508&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3634201</ArticleId><ArticleId IdType="pubmed">23543484</ArticleId></ArticleIdList></Reference><Reference><Citation>Torella A, Fanin M, Mutarelli M, Peterle E, Del Vecchio Blanco F, Rispoli R, et al. Next-generation sequencing identifies transportin 3 as the causative gene for LGMD1F. PLoS One. 2013;8:e63536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3646821</ArticleId><ArticleId IdType="pubmed">23667635</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa R, Rodia MT, Vianello S, Santi S, Lattanzi G, Angelini C, et al. Transportin 3 (TNPO3) and related proteins in limb girdle muscular dystrophy D2 muscle biopsies: A morphological study and pathogenetic hypothesis. Neuromuscul Disord. 2020;30:685&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">32690349</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura M, Morinaka Y, Imai K, Kose S, Horton P, Imamoto N. Extensive cargo identification reveals distinct biological roles of the 12 importin pathways. Elife. 2017;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5305215</ArticleId><ArticleId IdType="pubmed">28117667</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka N, Bachorik JL, Dreyfuss G. Transportin-SR, a nuclear import receptor for SR proteins. J Cell Biol. 1999;145:1145&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2133142</ArticleId><ArticleId IdType="pubmed">10366588</ArticleId></ArticleIdList></Reference><Reference><Citation>Lester E, Ooi FK, Bakkar N, Ayers J, Woerman AL, Wheeler J, et al. Tau aggregates are RNA-protein assemblies that mislocalize multiple nuclear speckle components. Neuron. 2021;109:1675&#x2013;91 e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8141031</ArticleId><ArticleId IdType="pubmed">33848474</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan PJ, Strovas TJ, Baum M, Mitchell BK, Eck RJ, Hendricks N, et al. Pathological tau drives ectopic nuclear speckle scaffold protein SRRM2 accumulation in neuron cytoplasm in Alzheimer&#x2019;s disease. Acta Neuropathol Commun. 2021;9:117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8243890</ArticleId><ArticleId IdType="pubmed">34187600</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorenberg EL, Shorter J. Tau heckles speckles: A pathogenic mechanism in tauopathy? Neuron. 2021;109:1585&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">34015263</ArticleId></ArticleIdList></Reference><Reference><Citation>Safari MS, King MR, Brangwynne CP, Petry S. Interaction of spindle assembly factor TPX2 with importins-alpha/beta inhibit protein phase separation. J Biol Chem. 2021:100998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8390506</ArticleId><ArticleId IdType="pubmed">34302807</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura M, Imai K, Morinaka Y, Hosono-Sakuma Y, Horton P, Imamoto N. Distinct mutations in importin-&#x3b2; family nucleocytoplasmic transport receptors transportin-SR and importin-13 affect specific cargo binding. Scientific Reports. 2021;11:15649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8329185</ArticleId><ArticleId IdType="pubmed">34341383</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosyna FK, Depping R. Controlling the Gatekeeper: Therapeutic Targeting of Nuclear Transport. Cells. 2018;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6262578</ArticleId><ArticleId IdType="pubmed">30469340</ArticleId></ArticleIdList></Reference><Reference><Citation>Floer M, Blobel G, Rexach M. Disassembly of RanGTP-karyopherin beta complex, an intermediate in nuclear protein import. J Biol Chem. 1997;272:19538&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">9235958</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BJ, Cansizoglu AE, Suel KE, Louis TH, Zhang Z, Chook YM. Rules for nuclear localization sequence recognition by karyopherin beta 2. Cell. 2006;126:543&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3442361</ArticleId><ArticleId IdType="pubmed">16901787</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith KM, Tsimbalyuk S, Edwards MR, Cross EM, Batra J, Soares da Costa TP, et al. Structural basis for importin alpha 3 specificity of W proteins in Hendra and Nipah viruses. Nat Commun. 2018;9:3703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6135763</ArticleId><ArticleId IdType="pubmed">30209309</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama M, Matsuura Y. Crystal structure of importin-&#x3b1;3 bound to the nuclear localization signal of Ran-binding protein 3. Biochemical and biophysical research communications. 2017;491:609&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">28760339</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H, Takeshima T, Nakagawa T, MacMillan KS, Wynn RM, Wang H, et al. The structure of importin &#x3b1; and the nuclear localization peptide of ChREBP, and small compound inhibitors of ChREBP-importin &#x3b1; interactions. Biochem J. 2020;477:3253&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489895</ArticleId><ArticleId IdType="pubmed">32776146</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby TW, Pedersen LC, Gabel SA, Gassman NR, London RE. Variations in nuclear localization strategies among pol X family enzymes. Traffic. 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6684861</ArticleId><ArticleId IdType="pubmed">29931796</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby TW, Gassman NR, Smith CE, Pedersen LC, Gabel SA, Sobhany M, et al. Nuclear Localization of the DNA Repair Scaffold XRCC1: Uncovering the Functional Role of a Bipartite NLS. Sci Rep. 2015;5:13405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4548243</ArticleId><ArticleId IdType="pubmed">26304019</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong SA, Kim K, Lee JH, Cha JS, Khadka P, Cho HS, et al. Akt-mediated phosphorylation increases the binding affinity of hTERT for importin &#x3b1; to promote nuclear translocation. J Cell Sci. 2015;128:2287&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">25999477</ArticleId></ArticleIdList></Reference><Reference><Citation>Neef DW, Jaeger AM, Gomez-Pastor R, Willmund F, Frydman J, Thiele DJ. A direct regulatory interaction between chaperonin TRiC and stress-responsive transcription factor HSF1. Cell Rep. 2014;9:955&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4488849</ArticleId><ArticleId IdType="pubmed">25437552</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigh L, Literati PN, Horvath I, Torok Z, Balogh G, Glatz A, et al. Bimoclomol: a nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects. Nat Med. 1997;3:1150&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9334730</ArticleId></ArticleIdList></Reference><Reference><Citation>Hargitai J, Lewis H, Boros I, R&#xe1;cz T, Fiser A, Kurucz I, et al. Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochemical and biophysical research communications. 2003;307:689&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">12893279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, Greensmith L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med. 2004;10:402&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15034571</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed M, Machado PM, Miller A, Spicer C, Herbelin L, He J, et al. Targeting protein homeostasis in sporadic inclusion body myositis. Sci Transl Med. 2016;8:331ra41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5043094</ArticleId><ArticleId IdType="pubmed">27009270</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackrel ME, Shorter J. Shock and awe: unleashing the heat shock response to treat Huntington disease. J Clin Invest. 2011;121:2972&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3148752</ArticleId><ArticleId IdType="pubmed">21785212</ArticleId></ArticleIdList></Reference><Reference><Citation>Auluck PK, Bonini NM. Pharmacological prevention of Parkinson disease in Drosophila. Nat Med. 2002;8:1185&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12411925</ArticleId></ArticleIdList></Reference><Reference><Citation>Burslem GM, Crews CM. Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery. Cell. 2020;181:102&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319047</ArticleId><ArticleId IdType="pubmed">31955850</ArticleId></ArticleIdList></Reference><Reference><Citation>Levone BR, Lenzken SC, Antonaci M, Maiser A, Rapp A, Conte F, et al. FUS-dependent liquid-liquid phase separation is important for DNA repair initiation. J Cell Biol. 2021;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953258</ArticleId><ArticleId IdType="pubmed">33704371</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra J, Guerrero EN, Hegde PM, Liachko NF, Wang H, Vasquez V, et al. Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proc Natl Acad Sci U S A. 2019;116:4696&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410842</ArticleId><ArticleId IdType="pubmed">30770445</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami NH, Smith RB, Carrasco MA, Williams LA, Winborn CS, Han SSW, et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014;81:536&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopal PP, Nirschl JJ, Klinman E, Holzbaur EL. Amyotrophic lateral sclerosis-linked mutations increase the viscosity of liquid-like TDP-43 RNP granules in neurons. Proc Natl Acad Sci U S A. 2017;114:E2466&#x2013;e75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5373408</ArticleId><ArticleId IdType="pubmed">28265061</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallegger M, Chakrabarti AM, Lee FCY, Lee BL, Amalietti AG, Odeh HM, et al. TDP-43 condensation properties specify its RNA-binding and regulatory repertoire. Cell. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8445024</ArticleId><ArticleId IdType="pubmed">34380047</ArticleId></ArticleIdList></Reference><Reference><Citation>Deverman BE, Ravina BM, Bankiewicz KS, Paul SM, Sah DWY. Gene therapy for neurological disorders: progress and prospects. Nature reviews Drug discovery. 2018;17:641&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">30093643</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo-Hernandez M, Tadokoro T, Navarro MR, Platoshyn O, Kobayashi Y, Marsala S, et al. Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS. Nat Med. 2020;26:118&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8171115</ArticleId><ArticleId IdType="pubmed">31873312</ArticleId></ArticleIdList></Reference><Reference><Citation>Naldini L Gene therapy returns to centre stage. Nature. 2015;526:351&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">26469046</ArticleId></ArticleIdList></Reference><Reference><Citation>LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, et al. AAV2-GAD gene therapy for advanced Parkinson&#x2019;s disease: a double-blind, sham-surgery controlled, randomised trial. The Lancet Neurology. 2011;10:309&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">21419704</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. The New England journal of medicine. 2017;377:1713&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091557</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Annals of neurology. 2015;78:248&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">26061140</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzmin DA, Shutova MV, Johnston NR, Smith OP, Fedorin VV, Kukushkin YS, et al. The clinical landscape for AAV gene therapies. Nature reviews Drug discovery. 2021;20:173&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">33495615</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nature reviews Drug discovery. 2019;18:358&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6927556</ArticleId><ArticleId IdType="pubmed">30710128</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, et al. Current Clinical Applications of In Vivo Gene Therapy with AAVs. Mol Ther. 2021;29:464&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7854298</ArticleId><ArticleId IdType="pubmed">33309881</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, Fischbeck KH. Maybe too much of a good thing in gene therapy. Nat Neurosci. 2021;24:901&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">34131327</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Alstyne M, Tattoli I, Delestree N, Recinos Y, Workman E, Shihabuddin LS, et al. Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit. Nat Neurosci. 2021;24:930&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8254787</ArticleId><ArticleId IdType="pubmed">33795885</ArticleId></ArticleIdList></Reference><Reference><Citation>Kormann MS, Hasenpusch G, Aneja MK, Nica G, Flemmer AW, Herber-Jonat S, et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol. 2011;29:154&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21217696</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N, Weissman D. Development of vaccines and antivirals for combating viral pandemics. Nat Biomed Eng. 2020;4:1128&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8336060</ArticleId><ArticleId IdType="pubmed">33293724</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Z, Chen C, Christiansen A, Ji S, Lin Q, Anumonwo C, et al. Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome. Sci Transl Med. 2020;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">32848094</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim KH, Han Z, Jeon HY, Kach J, Jing E, Weyn-Vanhentenryck S, et al. Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression. Nat Commun. 2020;11:3501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7347940</ArticleId><ArticleId IdType="pubmed">32647108</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nature reviews Drug discovery. 2020;19:673&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7419031</ArticleId><ArticleId IdType="pubmed">32782413</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Reebye V, Hitchen P, Fan J, Jiang H, Saetrom P, et al. Mechanisms involved in the activation of C/EBPalpha by small activating RNA in hepatocellular carcinoma. Oncogene. 2019;38:3446&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">30643190</ArticleId></ArticleIdList></Reference><Reference><Citation>Berchtold NC, Cribbs DH, Coleman PD, Rogers J, Head E, Kim R, et al. Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A. 2008;105:15605&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2563070</ArticleId><ArticleId IdType="pubmed">18832152</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogler TO, Wheeler JR, Nguyen ED, Hughes MP, Britson KA, Lester E, et al. TDP-43 and RNA form amyloid-like myo-granules in regenerating muscle. Nature. 2018;563:508&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324568</ArticleId><ArticleId IdType="pubmed">30464263</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda K, Clatterbuck-Soper SF, Jackrel ME, Shorter J, Mili S. FUS inclusions disrupt RNA localization by sequestering kinesin-1 and inhibiting microtubule detyrosination. J Cell Biol. 2017;216:1015&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5379945</ArticleId><ArticleId IdType="pubmed">28298410</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda K, Zhang H, Loiselle D, Haystead T, Macara IG, Mili S. The RNA-binding protein Fus directs translation of localized mRNAs in APC-RNP granules. J Cell Biol. 2013;203:737&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857475</ArticleId><ArticleId IdType="pubmed">24297750</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>